JP2015528012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528012A5 JP2015528012A5 JP2015523279A JP2015523279A JP2015528012A5 JP 2015528012 A5 JP2015528012 A5 JP 2015528012A5 JP 2015523279 A JP2015523279 A JP 2015523279A JP 2015523279 A JP2015523279 A JP 2015523279A JP 2015528012 A5 JP2015528012 A5 JP 2015528012A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- dosage form
- mol
- subject
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 117
- 239000002552 dosage form Substances 0.000 claims description 98
- 239000002585 base Substances 0.000 claims description 80
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 37
- -1 hydrogen cations Chemical class 0.000 claims description 33
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 26
- 239000000178 monomer Substances 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000003431 cross linking reagent Substances 0.000 claims description 21
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 16
- 229910052749 magnesium Inorganic materials 0.000 claims description 16
- 239000011777 magnesium Substances 0.000 claims description 16
- 235000010216 calcium carbonate Nutrition 0.000 claims description 15
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 11
- 208000002682 Hyperkalemia Diseases 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 8
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004185 ester group Chemical group 0.000 claims description 6
- 125000001033 ether group Chemical group 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 4
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 4
- 150000008044 alkali metal hydroxides Chemical group 0.000 claims description 4
- 229910000272 alkali metal oxide Inorganic materials 0.000 claims description 4
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 4
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
- 229940118662 aluminum carbonate Drugs 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 4
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000920 calcium hydroxide Substances 0.000 claims description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 4
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000292 calcium oxide Substances 0.000 claims description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 4
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 4
- 239000001095 magnesium carbonate Substances 0.000 claims description 4
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 4
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 4
- 239000000347 magnesium hydroxide Substances 0.000 claims description 4
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 229940049920 malate Drugs 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000001508 potassium citrate Substances 0.000 claims description 4
- 229960002635 potassium citrate Drugs 0.000 claims description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 4
- 235000011082 potassium citrates Nutrition 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 description 240
- 239000000203 mixture Substances 0.000 description 169
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 37
- 229960003975 potassium Drugs 0.000 description 37
- 229910052700 potassium Inorganic materials 0.000 description 37
- 239000011591 potassium Substances 0.000 description 37
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 26
- 206010030113 Oedema Diseases 0.000 description 26
- 230000036772 blood pressure Effects 0.000 description 26
- 229910052708 sodium Inorganic materials 0.000 description 26
- 239000011734 sodium Substances 0.000 description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 24
- 229910052791 calcium Inorganic materials 0.000 description 24
- 239000011575 calcium Substances 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 21
- 206010016803 Fluid overload Diseases 0.000 description 20
- 150000002500 ions Chemical class 0.000 description 20
- 230000004584 weight gain Effects 0.000 description 20
- 235000019786 weight gain Nutrition 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 206010003445 Ascites Diseases 0.000 description 17
- 208000000059 Dyspnea Diseases 0.000 description 17
- 206010013975 Dyspnoeas Diseases 0.000 description 17
- 206010020772 Hypertension Diseases 0.000 description 17
- 208000020832 chronic kidney disease Diseases 0.000 description 17
- 206010037423 Pulmonary oedema Diseases 0.000 description 16
- 238000000502 dialysis Methods 0.000 description 16
- 238000011863 diuretic therapy Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 208000005333 pulmonary edema Diseases 0.000 description 14
- TYCFGHUTYSLISP-UHFFFAOYSA-N 2-fluoroprop-2-enoic acid Chemical group OC(=O)C(F)=C TYCFGHUTYSLISP-UHFFFAOYSA-N 0.000 description 13
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 12
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 12
- XWJBRBSPAODJER-UHFFFAOYSA-N 1,7-octadiene Chemical compound C=CCCCCC=C XWJBRBSPAODJER-UHFFFAOYSA-N 0.000 description 12
- 206010030124 Oedema peripheral Diseases 0.000 description 12
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 12
- 229960002576 amiloride Drugs 0.000 description 12
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 12
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 12
- 239000004971 Cross linker Substances 0.000 description 11
- 206010029164 Nephrotic syndrome Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 210000000476 body water Anatomy 0.000 description 10
- 150000004820 halides Chemical group 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 206010019280 Heart failures Diseases 0.000 description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 8
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 8
- 208000021017 Weight Gain Diseases 0.000 description 8
- 229910052744 lithium Inorganic materials 0.000 description 8
- 208000013220 shortness of breath Diseases 0.000 description 8
- 229960001288 triamterene Drugs 0.000 description 8
- 208000029422 Hypernatremia Diseases 0.000 description 7
- 208000028208 end stage renal disease Diseases 0.000 description 7
- 201000000523 end stage renal failure Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 6
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 6
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 6
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 6
- 102000008873 Angiotensin II receptor Human genes 0.000 description 6
- 108050000824 Angiotensin II receptor Proteins 0.000 description 6
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 6
- 239000002083 C09CA01 - Losartan Substances 0.000 description 6
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 6
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 6
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 6
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 6
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 6
- 235000001258 Cinchona calisaya Nutrition 0.000 description 6
- 241000208011 Digitalis Species 0.000 description 6
- 108010061435 Enalapril Proteins 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 108010007859 Lisinopril Proteins 0.000 description 6
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 6
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 6
- 229940122767 Potassium sparing diuretic Drugs 0.000 description 6
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 6
- 229960002122 acebutolol Drugs 0.000 description 6
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 6
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 6
- 229940083712 aldosterone antagonist Drugs 0.000 description 6
- 239000002170 aldosterone antagonist Substances 0.000 description 6
- 229960005260 amiodarone Drugs 0.000 description 6
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 6
- 229960000836 amitriptyline Drugs 0.000 description 6
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 229960002274 atenolol Drugs 0.000 description 6
- 229960004530 benazepril Drugs 0.000 description 6
- 239000002876 beta blocker Substances 0.000 description 6
- 229940097320 beta blocking agent Drugs 0.000 description 6
- 229960004324 betaxolol Drugs 0.000 description 6
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 6
- 229960002781 bisoprolol Drugs 0.000 description 6
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 6
- 229960000932 candesartan Drugs 0.000 description 6
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 6
- 229960000830 captopril Drugs 0.000 description 6
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 6
- 229960001222 carteolol Drugs 0.000 description 6
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 6
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 6
- 229960003291 chlorphenamine Drugs 0.000 description 6
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 6
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 6
- 229960000876 cinnarizine Drugs 0.000 description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 6
- 229960000873 enalapril Drugs 0.000 description 6
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 6
- 229960002179 ephedrine Drugs 0.000 description 6
- 229960001208 eplerenone Drugs 0.000 description 6
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 6
- 229960004563 eprosartan Drugs 0.000 description 6
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 229940091249 fluoride supplement Drugs 0.000 description 6
- 229960002464 fluoxetine Drugs 0.000 description 6
- 229960002490 fosinopril Drugs 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 6
- 229960004801 imipramine Drugs 0.000 description 6
- 229960002198 irbesartan Drugs 0.000 description 6
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 6
- 229960004125 ketoconazole Drugs 0.000 description 6
- 229960002394 lisinopril Drugs 0.000 description 6
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 6
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 6
- 229960001571 loperamide Drugs 0.000 description 6
- 229960004773 losartan Drugs 0.000 description 6
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 6
- 239000003055 low molecular weight heparin Substances 0.000 description 6
- 229940127215 low-molecular weight heparin Drugs 0.000 description 6
- 229960000423 loxapine Drugs 0.000 description 6
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 6
- 229960005170 moexipril Drugs 0.000 description 6
- 229960004255 nadolol Drugs 0.000 description 6
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 229960001158 nortriptyline Drugs 0.000 description 6
- 229960002582 perindopril Drugs 0.000 description 6
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 6
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 6
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 6
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 6
- 229960004134 propofol Drugs 0.000 description 6
- 229960003712 propranolol Drugs 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 6
- 229960001455 quinapril Drugs 0.000 description 6
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 6
- 229960000948 quinine Drugs 0.000 description 6
- 229960003401 ramipril Drugs 0.000 description 6
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 6
- 239000003087 receptor blocking agent Substances 0.000 description 6
- 229960002370 sotalol Drugs 0.000 description 6
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 6
- 229960002256 spironolactone Drugs 0.000 description 6
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 6
- 229940032712 succinylcholine Drugs 0.000 description 6
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 6
- 229960005187 telmisartan Drugs 0.000 description 6
- 150000003512 tertiary amines Chemical class 0.000 description 6
- 229960002051 trandolapril Drugs 0.000 description 6
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 6
- 229960001082 trimethoprim Drugs 0.000 description 6
- 229960004699 valsartan Drugs 0.000 description 6
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 6
- 230000004872 arterial blood pressure Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 239000002395 mineralocorticoid Substances 0.000 description 5
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 4
- LEJBBGNFPAFPKQ-UHFFFAOYSA-N 2-(2-prop-2-enoyloxyethoxy)ethyl prop-2-enoate Chemical group C=CC(=O)OCCOCCOC(=O)C=C LEJBBGNFPAFPKQ-UHFFFAOYSA-N 0.000 description 4
- LWCDSJZGNUDNCO-UHFFFAOYSA-N 2-fluorobut-2-enoic acid Chemical compound CC=C(F)C(O)=O LWCDSJZGNUDNCO-UHFFFAOYSA-N 0.000 description 4
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 4
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 4
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 206010038687 Respiratory distress Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 229960002478 aldosterone Drugs 0.000 description 4
- 229960004601 aliskiren Drugs 0.000 description 4
- 229940052651 anticholinergic tertiary amines Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 229960005057 canrenone Drugs 0.000 description 4
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001269 cardiogenic effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 208000014987 limb edema Diseases 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 208000009928 nephrosis Diseases 0.000 description 4
- 231100001027 nephrosis Toxicity 0.000 description 4
- 230000037081 physical activity Effects 0.000 description 4
- 208000015658 resistant hypertension Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960004605 timolol Drugs 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- PADGNZFOVSZIKZ-UHFFFAOYSA-N 2-(chloromethyl)oxirane;hydrogen carbonate;prop-2-enylazanium Chemical compound NCC=C.OC(O)=O.ClCC1CO1 PADGNZFOVSZIKZ-UHFFFAOYSA-N 0.000 description 2
- BXAAQNFGSQKPDZ-UHFFFAOYSA-N 3-[1,2,2-tris(prop-2-enoxy)ethoxy]prop-1-ene Chemical compound C=CCOC(OCC=C)C(OCC=C)OCC=C BXAAQNFGSQKPDZ-UHFFFAOYSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 208000020576 Adrenal disease Diseases 0.000 description 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 2
- 206010060934 Allergic oedema Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229940097420 Diuretic Drugs 0.000 description 2
- 206010013647 Drowning Diseases 0.000 description 2
- 206010014357 Electric shock Diseases 0.000 description 2
- 206010015993 Eyelid oedema Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010019345 Heat stroke Diseases 0.000 description 2
- 206010020844 Hyperthermia malignant Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 206010020944 Hypoaldosteronism Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010025282 Lymphoedema Diseases 0.000 description 2
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010029538 Non-cardiogenic pulmonary oedema Diseases 0.000 description 2
- 229940079172 Osmotic diuretic Drugs 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 208000026980 Renal tubular disease Diseases 0.000 description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 description 2
- 206010057431 Scleral oedema Diseases 0.000 description 2
- KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 description 2
- 206010041277 Sodium retention Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 229940121792 Thiazide diuretic Drugs 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000008445 altitude sickness Diseases 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 229960000724 cidofovir Drugs 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- FMTDIUIBLCQGJB-SEYHBJAFSA-N demeclocycline Chemical compound C1([C@@H](O)[C@H]2C3)=C(Cl)C=CC(O)=C1C(=O)C2=C(O)[C@@]1(O)[C@@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FMTDIUIBLCQGJB-SEYHBJAFSA-N 0.000 description 2
- 229960002398 demeclocycline Drugs 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 208000011318 facial edema Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 229960001078 lithium Drugs 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- 208000002502 lymphedema Diseases 0.000 description 2
- 201000007004 malignant hyperthermia Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 2
- 229960002455 methoxyflurane Drugs 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 239000002337 osmotic diuretic agent Substances 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 229940070017 potassium supplement Drugs 0.000 description 2
- FBCQUCJYYPMKRO-UHFFFAOYSA-N prop-2-enyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC=C FBCQUCJYYPMKRO-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 208000014318 renal tubule disease Diseases 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229960005441 sevelamer carbonate Drugs 0.000 description 2
- 229960003027 sevelamer hydrochloride Drugs 0.000 description 2
- 208000026773 severe abdominal cramp Diseases 0.000 description 2
- 229940091252 sodium supplement Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- VPYJNCGUESNPMV-UHFFFAOYSA-N triallylamine Chemical compound C=CCN(CC=C)CC=C VPYJNCGUESNPMV-UHFFFAOYSA-N 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- OYKPJMYWPYIXGG-UHFFFAOYSA-N 2,2-dimethylbutane;prop-2-enoic acid Chemical compound OC(=O)C=C.OC(=O)C=C.OC(=O)C=C.CCC(C)(C)C OYKPJMYWPYIXGG-UHFFFAOYSA-N 0.000 description 1
- 229920006079 Pentamid® Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- ZTZJVAOTIOAZGZ-UHFFFAOYSA-N methyl 2-fluoroacrylate Chemical compound COC(=O)C(F)=C ZTZJVAOTIOAZGZ-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261673707P | 2012-07-19 | 2012-07-19 | |
| US61/673,707 | 2012-07-19 | ||
| PCT/US2013/051253 WO2014015240A1 (en) | 2012-07-19 | 2013-07-19 | Compositions comprising crosslinked cation-binding polymers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017203453A Division JP6423506B2 (ja) | 2012-07-19 | 2017-10-20 | 架橋型カチオン結合性ポリマーを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528012A JP2015528012A (ja) | 2015-09-24 |
| JP2015528012A5 true JP2015528012A5 (enExample) | 2016-08-25 |
| JP6232062B2 JP6232062B2 (ja) | 2017-11-15 |
Family
ID=49949269
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523279A Expired - Fee Related JP6232062B2 (ja) | 2012-07-19 | 2013-07-19 | 架橋型カチオン結合性ポリマーを含む組成物 |
| JP2017203453A Expired - Fee Related JP6423506B2 (ja) | 2012-07-19 | 2017-10-20 | 架橋型カチオン結合性ポリマーを含む組成物 |
| JP2018196631A Expired - Fee Related JP6600062B2 (ja) | 2012-07-19 | 2018-10-18 | 架橋型カチオン結合性ポリマーを含む組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017203453A Expired - Fee Related JP6423506B2 (ja) | 2012-07-19 | 2017-10-20 | 架橋型カチオン結合性ポリマーを含む組成物 |
| JP2018196631A Expired - Fee Related JP6600062B2 (ja) | 2012-07-19 | 2018-10-18 | 架橋型カチオン結合性ポリマーを含む組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150196585A1 (enExample) |
| EP (1) | EP2874633A4 (enExample) |
| JP (3) | JP6232062B2 (enExample) |
| KR (1) | KR102211670B1 (enExample) |
| CN (2) | CN105451746A (enExample) |
| AU (2) | AU2013292350B9 (enExample) |
| BR (1) | BR112015001230B1 (enExample) |
| CA (1) | CA2879425A1 (enExample) |
| DE (1) | DE112013003596T5 (enExample) |
| GB (1) | GB2519479B (enExample) |
| HK (1) | HK1203420A1 (enExample) |
| IN (1) | IN2015DN01369A (enExample) |
| MX (2) | MX2015000810A (enExample) |
| WO (1) | WO2014015240A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014015244A1 (en) * | 2012-07-19 | 2014-01-23 | Sorbent Therapeutics, Inc. | Compositions comprising crosslinked cation-binding polymers |
| AU2013329451B2 (en) | 2012-10-08 | 2018-08-09 | Vifor (International) Ltd. | Potassium-binding agents for treating hypertension and hyperkalemia |
| US20170022314A1 (en) | 2015-07-24 | 2017-01-26 | Weyerhaeuser Nr Company | Grafted crosslinked cellulose |
| US20170342383A1 (en) | 2016-05-27 | 2017-11-30 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
| EP3717428A1 (en) | 2017-11-28 | 2020-10-07 | Corning Incorporated | Bioactive borate glass and methods thereof |
| CN111417601A (zh) | 2017-11-28 | 2020-07-14 | 康宁股份有限公司 | 化学强化的生物活性玻璃陶瓷 |
| EP3717030A1 (en) | 2017-11-28 | 2020-10-07 | Corning Incorporated | Bioactive glass compositions and dentin hypersensitivity remediation |
| EP3717427A1 (en) | 2017-11-28 | 2020-10-07 | Corning Incorporated | High liquidus viscosity bioactive glass |
| CN108395497B (zh) * | 2018-01-22 | 2021-03-30 | 中国科学院兰州化学物理研究所 | 紫外荧光型空间润滑油爬行屏障材料 |
| US12435174B2 (en) * | 2018-04-10 | 2025-10-07 | Arkema Inc. | Functional fluoropolymers |
| WO2020097190A1 (en) * | 2018-11-06 | 2020-05-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of personalized treatment for cardiomyopathy and heart failure and associated diseases by measuring edema and cachexia/sarcopenia |
| JP2021192000A (ja) | 2018-12-28 | 2021-12-16 | フォルシアクラリオン・エレクトロニクス株式会社 | 経路案内方法、端末装置、経路案内システム及びプログラム |
| US12280144B2 (en) * | 2019-12-19 | 2025-04-22 | Zaki Yusuf | Gel compositions for mitigation of burn injuries, kits containing the gel compositions, and associated methods |
| US11807700B2 (en) * | 2020-08-17 | 2023-11-07 | Saudi Arabian Oil Company | Electro-responsive hydrogel for reservoir and downhole application |
| ES2985514T3 (es) * | 2021-09-13 | 2024-11-06 | Waterstone Pharmaceuticals Wuhan Co Ltd | Medicamento polimérico para tratar la hiperpotasemia y método de preparación del mismo |
| CN115570900B (zh) * | 2022-09-28 | 2023-04-07 | 江西和烁丰新材料有限公司 | 一种环保型、可长久保存的热敏纸 |
| US12276180B2 (en) | 2023-05-17 | 2025-04-15 | Saudi Arabian Oil Company | Hydrogels for carbon sequestration and sealing zones in a wellbore |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524740A (en) * | 1976-11-09 | 1978-09-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions for use in the suppression of gastric reflux |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US8263112B2 (en) * | 2000-11-20 | 2012-09-11 | Sorbent Therapeutics, Inc. | In vivo use of water absorbent polymers |
| US20090042951A1 (en) * | 2004-02-20 | 2009-02-12 | Robert Danziger | Blood Pressure Reduction in Salt-Sensitive Hypertension |
| US8192758B2 (en) * | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| GB2430368B (en) * | 2004-03-30 | 2009-08-26 | Ilypsa Inc | Methods and compositions for treatment of ion imbalances |
| WO2007067570A1 (en) * | 2005-12-05 | 2007-06-14 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of disease |
| EP2601981A1 (en) * | 2007-08-29 | 2013-06-12 | Sorbent Therapeutics, Inc. | Absorbent polymeric compositions with varying counterion content and their methods of preparation and use |
| WO2010022381A1 (en) * | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| US20100111892A1 (en) * | 2008-08-22 | 2010-05-06 | Relypsa, Inc. | Crosslinked polyfluoroacrylic acid and processes for the preparation thereof |
| CN103919792B (zh) * | 2008-08-22 | 2018-03-09 | 瑞立普萨公司 | 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用 |
| CN101385500A (zh) * | 2008-10-30 | 2009-03-18 | 九三粮油工业集团有限公司 | 超临界co2萃取大豆粉末磷脂的连续工业化生产工艺 |
| CA2824391A1 (en) * | 2011-01-10 | 2012-07-19 | Sorbent Therapeutics, Inc. | Compositions comprising crosslinked cation-binding polymers and a base, uses thereof |
-
2013
- 2013-07-19 US US14/415,409 patent/US20150196585A1/en not_active Abandoned
- 2013-07-19 WO PCT/US2013/051253 patent/WO2014015240A1/en not_active Ceased
- 2013-07-19 CN CN201380048838.1A patent/CN105451746A/zh active Pending
- 2013-07-19 CN CN201910176991.1A patent/CN110051686A/zh active Pending
- 2013-07-19 HK HK15104264.4A patent/HK1203420A1/xx unknown
- 2013-07-19 GB GB1502802.0A patent/GB2519479B/en not_active Expired - Fee Related
- 2013-07-19 BR BR112015001230A patent/BR112015001230B1/pt not_active IP Right Cessation
- 2013-07-19 EP EP13820528.1A patent/EP2874633A4/en not_active Withdrawn
- 2013-07-19 AU AU2013292350A patent/AU2013292350B9/en not_active Ceased
- 2013-07-19 DE DE112013003596.0T patent/DE112013003596T5/de not_active Withdrawn
- 2013-07-19 MX MX2015000810A patent/MX2015000810A/es unknown
- 2013-07-19 CA CA2879425A patent/CA2879425A1/en not_active Abandoned
- 2013-07-19 KR KR1020157004448A patent/KR102211670B1/ko not_active Expired - Fee Related
- 2013-07-19 IN IN1369DEN2015 patent/IN2015DN01369A/en unknown
- 2013-07-19 JP JP2015523279A patent/JP6232062B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-16 MX MX2020010456A patent/MX2020010456A/es unknown
-
2017
- 2017-10-20 JP JP2017203453A patent/JP6423506B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-18 JP JP2018196631A patent/JP6600062B2/ja not_active Expired - Fee Related
- 2018-10-31 AU AU2018256550A patent/AU2018256550B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528012A5 (enExample) | ||
| JP6600062B2 (ja) | 架橋型カチオン結合性ポリマーを含む組成物 | |
| JP5421511B2 (ja) | 胃に留まるガバペンチン投薬を使用する処置方法 | |
| EP3741747B1 (en) | Method for preventing and/or treating anxiety | |
| JP2004517148A (ja) | 心機能不全および心不全の治療における必須ｎ−３脂肪酸 | |
| JP2019108336A (ja) | ピロリジン誘導体の経口製剤 | |
| KR20240162167A (ko) | 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물 | |
| EP4197543A1 (en) | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers | |
| TWI331920B (en) | Unit dosage form for relieving or treating constipation in human patients | |
| CN103596555A (zh) | 包含交联的阳离子-结合聚合物和钙和/或镁阳离子的组合物及其用途 | |
| CN113768863A (zh) | L-鸟氨酸苯乙酸盐制剂 | |
| RS59303B1 (sr) | Spojnica | |
| TW201813645A (zh) | 含鹽皮質激素受體拮抗劑的藥物組合物及其用途 | |
| CN106163518B (zh) | 包含血管紧张素-Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的药物组合制剂 | |
| CN104394865B (zh) | 稳定性提高的包含氨氯地平和氯沙坦的组合物 | |
| KR101265491B1 (ko) | 사포그릴레이트염산염을 함유하는 용출률이 조절된 경구용 다층정제 및 이의 제조방법 | |
| Rastogi et al. | New agents in treatment of hyperkalemia: an opportunity to optimize use of RAAS inhibitors for blood pressure control and organ protection in patients with chronic kidney disease | |
| KR20220119005A (ko) | 투석 이행 또는 신장사의 억제를 위한 약제 | |
| JP5923044B2 (ja) | 活性成分としてｌ−カルニチンまたはプロピオニルｌ−カルニチンを含む慢性静脈不全の予防または治療のための併用組成物 | |
| EP4356974A1 (en) | Combination of lactose and citric acid useful to modulate the immune system | |
| CN112043691A (zh) | 一种药物组合物及其用途 | |
| Efanov et al. | ARTERIAL HYPERTENSION CONTROL IN THE EXTREME NORTH POPULATION OF THE EMPLOYABLE AGE: PP. 34.397 | |
| WO2025017193A1 (en) | Methods of treating cardiomyopathy induced by metabolic inflexibility | |
| Santoso et al. | A randomized placebo controlled trial of endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic Heart Failure (END-HF) | |
| Rekovets et al. | INFLUENCE DIFFERENT TYPE OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION (AH) AND METABOLIC SYNDROME (MS) ON INSULIN RESISTANCE DEPENDS ON SEX: PP. 34.398 |